News & Events
Welcome to the NanoVation TherapeuticsTM newsroom
NanoVationtx™ News & Events
News of breakthroughs on the front lines of therapeutic innovation. Events featuring NVTx™ research & talent.
NanoVation Therapeutics has been awarded the prestigious Deal of the Year award at the 27th Annual Life Sciences BC Awards.
Co-founders Drs Pieter Cullis and Jay Kulkarni are interviewed by Biotech TV about developments in LNP science and NanoVation's work.
NanoVation Therapeutics today announced the expansion of its Board of Directors and the close of a funding round led by Convergent Ventures
CEO Dom Witzigmann presents on "Advancing lipid nanoparticles for safe and efficient nucleic acid delivery to extrahepatic tissues" at CLINAM 2023.
NVTx leaders Drs Pieter Cullis and Dominik Witzigmann presented in the ETPN webinar "Next Generation LNP Technologies for Extra-Hepatic Nucleic Acid Delivery"
NanoVation is eligible to receive up to ~US$600M and royalties in multi-year deal aimed at enabling nucleic acid delivery to cells outside of the liver
NanoVation Co-founder & CSO Jay Kulkarni was interviewed for the BIO Podcast at the BIO International Convention in San Diego in June 2024.
The first chemistry paper from NanoVation research, published in the Journal of Organic Chemistry, explores the Claisen self-condensation of lactones under Mukaiyama conditions using TiCl4 and triethylamine.
NanoVation Co-founder & CEO Dominik Witzigmann was interviewed at the Applied Biophysics Forum in Copenhagen in May 2024.
Our CSO Jayesh Kulkarni highlighted our trailblazing work in genetic medicines, in the “BC Delegation Spotlight: BIO San Diego” virtual event, hosted by Life Sciences BC (LSBC).
Dr. Stevens, esteemed Oxford professor and scientific advisor and board member for NanoVation Therapeutics UK, will present at the Scandinavian Society for Biomaterials (ScSB) Annual Meeting on April 24th, 2024.
The Canadian Medical Hall of Fame (CMHF) has named NanoVation Therapeutics co-founder and Board Chair Dr. Pieter Cullis one of its 2024 inductees, recognizing him as an icon of Canadian health leadership.
Pieter Cullis, our Board Chair and co-founder, alongside Jayesh Kulkarni, our Chief Scientific Officer, will take the stage at the Castle Delivery Meeting Redux in Sicily on April 7th.
Pieter Cullis is keynote speaker at the MSKCC's Molecular Pharmacology and Chemical Biology Research Seminar Series in New York.
This landmark publication, showcasing work by NanoVation Therapeutics co-founders Drs Pieter Cullis & Dominik Witzigmann, introduces a revolutionary magnetic separation technique that transforms the way we isolate and analyze the biomolecular corona of lipid nanoparticles.
Our CEO, Dominik Witzigmann, PhD, will be representing NanoVation Therapeutics at the RNA Leaders Europe 2024 conference in Basel!
NanoVation leaders will be at NMIN's 2024 Research Conference in Vancouver to deliver the Industry & Research keynote presentations.
Pieter Cullis, NVTx co-founder and Board Chair, takes centre stage at the Delivery of Nucleic Acid Therapeutics Meeting (Keystone Symposia) in Banff, Alberta.
Scientific Advisor & Board Member (UK) Molly Stevens has been appointed Dame of the Most Excellent Order of the British Empire for her outstanding services to Medicine.
This publication by NanoVation TherapeuticsTM co-founders Drs Christian Kastrup, Pieter Cullis, and Eric Jan, highlights groundbreaking cell therapy research that will shape the future of genetic medicines.
At the International mRNA Health Conference in Berlin, NanoVation TherapeuticsTM folks met with Nobel laureate Katalin Karikó, and our VP of Chemistry, Marco Ciufolini, presented on LNPs for gene therapy.
NanoVation Preclinical Immunology Scientist Jessica Silva presented a poster in the 2023 International Society for Vaccines in Lausanne, Switzerland.
NanoVation is a proud sponsor of the Vancouver RNA Club event next week at which NanoVation Senior Scientist, Formulation, Daniel Kurek, will present.
Board Chair Pieter Cullis and CEO Dominik Witzigmann were among the NanoVation TherapeuticsTM team members participating in the European Foundation for Clinical Nanomedicine (CLINAM) meeting in Basel.
Eric Jan, NanoVation Co-founder, hosts a mentoring lunch on Sept 25 as part of the 2023 RiboClub Annual Meeting in Quebec.
We're thrilled to announce that NanoVation Co-Founder Pieter Cullis will be keynote speaker at the Next-Generation Nanomedicine symposium.
Co-founder Dr. Christian Kastrup is presenting on Aug 15 in the Military Health System Research Symposium.
Co-Founder Dr. Pieter Cullis has been appointed to the Order of BC, the province's highest honour.
Co-founder Dr. Christian Kastrup will deliver a guest lecture at BC Children's Hospital Research Institute on August 2nd.
Co-Founder Dr. Pieter Cullis has been elected Fellow of the prestigious UK Royal Society.
Co-founder Pieter Cullis is a keynote speaker (with colleague Katalin Karikó) at the 5th Annual RNATx Conference, 21-23 June 2023 in Worcester, MA.
NanoVation team member Kevin An will be talking about NanoVation's lcLNP at the CBS Annual Meeting in Halifax this Thursday afternoon.
Arpan Desai will present an “Introduction to mRNA Based Therapeutics for COVID and Beyond” as part of Cambridge Wide Open Day on June 14.
Molly Stevens and Arpan Desai represented NanoVation at Nanomed Europe 23, discussing our next-generation LNPs for enabling genetic medicines.
CSO Jayesh Kulkarni will be showing off his LNP expertise in the Centre for Heart Lung Innovation (HLI) Seminar Series on June 2 at UBC.
Catch the May 17 presentation by NanoVation Formulation Scientist Kevin An at the ASGCT 26th Annual Meeting.
Co-Founder Dr. Pieter Cullis was honoured as the 19th D. Harold Copp Lecturer on 5 May.
Co-Founder Dr. Pieter Cullis, delivers a keynote talk & participates in a panel at a Gairdner Award event on May 9.
CSO Dr. Jayesh Kulkarni will discuss next-gen LNPs on a panel at the Institute of Technology in Immunobiology (ISI) 2023 in Brazil.
We'll be there! NanoVation is a proud co-sponsor of RNA Leaders Europe Congress (Basel, 15-16 March).
CSO Dr Jayesh Kulkarni will be talking at the LNP Immunogenicity & Toxicity Summit in Boston on Dec 8.
CEO Dominik Witzigmann will be part of the panel discussion focused on the potential of mRNA technology as a therapeutic platform at the BioFIT Event 2022 Conference in Strasbourg.
Our Chief Business Officer Don Enns is an invited speaker to the Blakes Breakfast Series, on Wednesday 16 Nov.
A project being led by NanoVation and Dr. Eric Jan of UBC has been awarded the maximum funding allotment available through BC Innovate's Ignite program.
The Board Chair and Co-Founder of NanoVation, Dr. Pieter Cullis, has received another honour in recognition of his pioneering work on the development of LNP delivery systems.
Hear our CSO Jayesh Kulkarni discuss the design of LNPs for extrahepatic gene therapy at this Oct 11 virtual mRNA Symposium organized by MilliporeSigma.
Baseimmune™ and NanoVation Therapeutics™ today announced their preclinical partnership program to accelerate the development of more effective vaccines against a range of infectious diseases.
The co-authors detail their efforts to broaden the application of LNPs in targeting non-hepatic tissues by developing LNP-based RNA therapies for the respiratory tract.
NanoVation’s Dr. Arpan Desai (UK) and co-authors describe the systematic optimisation of lipid-peptide nanocomplexes for the delivery of mRNA in two murine cancer cell types...
Co-authored by NanoVation’s Drs Jayesh Kulkarni & Pieter Cullis, this article develops a straightforward “bottom-up” approach to manufacture drug-loaded LNP-GNP systems.
This paper describes a synthesis of ALC-0315 by a sequence that more than doubles the overall yield relative to the published one, and that employs much cleaner reactions...
CSO Dr. Jayesh Kulkarni co-authored this article in The Plant Cell on monolignol export by diffusion down a polymerization-induced concentration gradient.
NanoVation CEO & Co-Founder Dr. Dominik Witzigmann co-organized a 2-day virtual symposium on “LNP-RNA Therapeutics: Beyond COVID.”
NanoVation Co-Founder Dr. Pieter Cullis and his colleagues Katalin Karikó and Drew Weissman were awarded the Gairdner International Award “for their pioneering work developing nucleoside-modified mRNA and LNP drug delivery..."
Dr. Arpan Desai co-authored this article on arrayed CRISPR screening to identify novel targets that enhance the productive delivery of mRNA by MC3-based LNPs.
Come hear CSO Dr. Jayesh Kulkarni discuss the composition of LNPs with respect to their efficacy & function.
NanoVation's Drs. Frederick Campbell, Dominik Witzigmann and Pieter Cullis co-authored this article on anionic LNPs that preferentially deliver mRNA to the hepatic reticuloendothelial system.
NanoVation Therapeutics is both a sponsor and speaker at the RNA leaders world Congress happening March 16-17th 2022.
Looking for for the next big hit to invest in in the biotech industry? Come listen to us pitch at the Ontario Bioscience Innovation Organization (OBIO) Investment Summit.
NanoVation UK's Dr. Arpan Desai co-authored this artilce on developing a high-throughput platform for screening LNPs for mRNA delivery.
Dr. Arpan Desai co-authored this artlce in SMALL on how mechanistic studies of an automated LNP revealed pharmaceutical properties associated with enhanced mRNA functional delivery.
CEO Dr. Witzigmann presents in-person at the 9th International mRNA Health Conference in Berlin, Germany
CEO Dr. Witzigmann delivered an invited talk during “Bringing drug delivery to the market” session of the 3rd CRIG Industrial Partnering Event.
CEO Dr. Witzigmann spoke at the International Symposium on Phospholipids in Pharmaceutical Research 2021.
NanoVation's Drs. Anthony Tam, Jayesh Kulkarni, Dominik Witzigmann and Pieter R Cullis co-authored this paper on FAM13A as potential therapeutic target in modulating airway tissue remodeling in COPD.
The Canadian Institutes of Health Research (CIHR) has highlighted the role of NanoVation's Dr. Pieter Cullis in developing the LNPs that have enabled mRNA vaccine development.
Listen to Dr. Pieter R Cullis on CBC radio's Quirks & Quarks, discussing the role of his work in the COVID 19 vaccines.
NanoVation co-organizes an Industry Educational Workshop as part of the Controlled Release Society Annual Meeting.
Dr. Jayesh Kulkarni co-authored this paper in Langmuir on the scalable production of LNPs containing Amphotericin B.
Three NanoVation co-founders wrote this review article in Nature Nanotechnology on the current landscape of nucleic acid therapeutics.
NanoVation's Drs Dominik Witzigmann and Pieter R Cullis published this article in Small, on optimized photoactivatable LNPs to enable red light-triggered drug release.
No results found.
Use the filters above to focus on news or events only, and/or to view the content from a specific year.
NTx webinar
WEBINAR: Next generation LNP technologies for enabling extra-hepatic nucleic acid delivery
An exclusive webinar hosted by the European Technology Platform on Nanomedicine (ETPN) and co-organized with NanoVation Therapeutics.
24 September 2024 | 5 pm CEST
- leading experts will discuss the latest advancements in lipid nanoparticle (LNP) technologies
- delve into cutting-edge innovations aimed at enabling the delivery of nucleic acids beyond the liver, opening new therapeutic avenues for a range of diseases
- a unique opportunity to gain insights from pioneers in the field of LNP technology and extrahepatic nucleic acid delivery
Welcome & Introduction by Prof. Raymond Schiffelers, Chairman of ETPN
Historical Perspective on LNP Development by Dr. Pieter Cullis, Professor & Entrepreneur, University of British Columbia (UBC)
Next Generation LNPs by Dr. Dominik Witzigmann, CEO of NanoVation Therapeutics
T Cell Applications by Dr. Laura Evgin, Assistant Professor, University of British Columbia (UBC)
Q&A Session moderated by Dr. Alexandre Ceccaldi, General Secretary of ETPN